Affinity maturation of humanized anti-epidermal growth factor receptor antibody using a modified phage-based open sandwich selection method

被引:4
|
作者
Sanada, Hideaki [1 ]
Kobayashi, Kazuki [1 ]
Oyama, Kenji [1 ]
Maru, Takamitsu [1 ]
Nakanishi, Takeshi [1 ]
Umetsu, Mitsuo [1 ]
Asano, Ryutaro [1 ,2 ]
Kumagai, Izumi [1 ]
机构
[1] Tohoku Univ, Grad Sch Engn, Dept Biomol Engn, Sendai, Miyagi 9808579, Japan
[2] Tokyo Univ Agr & Technol, Grad Sch Engn, Dept Biotechnol & Life Sci, Tokyo 1848588, Japan
来源
SCIENTIFIC REPORTS | 2018年 / 8卷
关键词
RESHAPING HUMAN-ANTIBODIES; BISPECIFIC ANTIBODY; THERMODYNAMIC CONSEQUENCES; CANCER-IMMUNOTHERAPY; MONOCLONAL-ANTIBODY; DISPLAY SYSTEM; DOMAIN ORDER; DIABODY; EGFR; STABILIZATION;
D O I
10.1038/s41598-018-23796-3
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Affinity maturation is one of the cardinal strategies for improving antibody function using in vitro evolutionary methods; one such well-established method is phage display. To minimise gene deletion, we previously developed an open sandwich (OS) method wherein selection was performed using only phage-displaying VH fragments after mixing with soluble VL fragments. The decrease in anti-EGFR antibody 528 affinity through humanization was successfully recovered by selecting VH mutants using this OS method. However, the affinity was not similar to that of parental 528. For further affinity maturation, we aimed to isolate VL mutants that act in synergy with VH mutants. However, the OS method could not be applied for selecting VL fragments because the preparation of soluble VH fragments was hampered by their instability and insolubility. Therefore, we initially designed a modified OS method based on domain-swapping of VH fragments, from added soluble Fv fragments to phagedisplaying VL fragments. Using this novel Fv-added OS selection method, we successfully isolated VL mutants, and one of the Fv comprising VH and VL mutants showed affinity almost equivalent to that of parental 528. This method is applicable for engineering other VL fragments for affinity maturation.
引用
收藏
页数:9
相关论文
共 45 条
  • [21] Impact of human papilloma virus infection on the response of head and neck cancers to anti-epidermal growth factor receptor antibody therapy
    M Pogorzelski
    S Ting
    T C Gauler
    F Breitenbuecher
    I Vossebein
    S Hoffarth
    J Markowetz
    S Lang
    C Bergmann
    S Brandau
    J A Jawad
    K W Schmid
    M Schuler
    S Kasper
    Cell Death & Disease, 2014, 5 : e1091 - e1091
  • [22] Engineering of an anti-epidermal growth factor receptor antibody to single chain format and labeling by sortase A-mediated protein ligation
    Madej, Mariusz P.
    Coia, Gregory
    Williams, Charlotte C.
    Caine, Joanne M.
    Pearce, Lesley A.
    Attwood, Rebecca
    Bartone, Nick A.
    Dolezal, Olan
    Nisbet, Rebecca M.
    Nuttall, Stewart D.
    Adams, Timothy E.
    BIOTECHNOLOGY AND BIOENGINEERING, 2012, 109 (06) : 1461 - 1470
  • [23] Impact of human papilloma virus infection on the response of head and neck cancers to anti-epidermal growth factor receptor antibody therapy
    Pogorzelski, M.
    Ting, S.
    Gauler, T. C.
    Breitenbuecher, F.
    Vossebein, I.
    Hoffarth, S.
    Markowetz, J.
    Lang, S.
    Bergmann, C.
    Brandau, S.
    Jawad, J. A.
    Schmid, K. W.
    Schuler, M.
    Kasper, S.
    CELL DEATH & DISEASE, 2014, 5 : e1091 - e1091
  • [24] Fibroblast growth factor and insulin-like growth factor differentially modulate the apoptosis and G1 arrest induced by anti-epidermal growth factor receptor monoclonal antibody
    Liu, BL
    Fang, M
    Lu, Y
    Mendelsohn, J
    Fan, Z
    ONCOGENE, 2001, 20 (15) : 1913 - 1922
  • [25] Treatment of malignant, non-resectable, epithelial origin esophageal tumors with the humanized anti-epidermal growth factor antibody nimotuzumab combined with radiation therapy and chemotherapy
    Ramos-Suzarte, Mayra
    Lorenzo-Luaces, Patricia
    Gonzalez Lazo, Nery
    Lima Perez, Mayte
    Luis Soriano, Jorge
    Viada Gonzalez, Carmen Elena
    Mendoza Hernadez, Ivis
    Avila Albuerne, Yisel
    Paredes Moreno, Beatriz
    Santiesteban Alvarez, Eduardo
    Pineda Callejo, Idael
    Alert, Jose
    Antonio Martell, Juan
    Santiesteban Gonzalez, Yanela
    Santiesteban Gonzalez, Yulainis
    Astudillo de la Vega, Horacio
    Ruiz-Garcia, Erika Betzabe
    Crombet-Ramos, Tania
    CANCER BIOLOGY & THERAPY, 2012, 13 (08) : 600 - 605
  • [26] Cytology-Based Gene Mutation Tests to Predict Response to Anti-Epidermal Growth Factor Receptor Therapy: A Review
    Malapelle, Umberto
    Bellevicine, Claudio
    Zeppa, Pio
    Palombini, Lucio
    Troncone, Giancarlo
    DIAGNOSTIC CYTOPATHOLOGY, 2011, 39 (09) : 703 - 710
  • [27] Anti-Epidermal Growth Factor Receptor Monoclonal Antibody Cetuximab Plus Doxorubicin in the Treatment of Metastatic Castration-Resistant Prostate Cancer
    Slovin, Susan F.
    Kelly, W. Kevin
    Wilton, Andrew
    Kattan, Michael
    Myskowski, Patricia
    Mendelsohn, John
    Scher, Howard I.
    CLINICAL GENITOURINARY CANCER, 2009, 7 (03) : E77 - E82
  • [28] Fibroblast growth factor and insulin-like growth factor differentially modulate the apoptosis and G1 arrest induced by anti-epidermal growth factor receptor monoclonal antibody
    Bolin Liu
    Min Fang
    Yang Lu
    John Mendelsohn
    Zhen Fan
    Oncogene, 2001, 20 : 1913 - 1922
  • [29] Anti-epidermal growth factor receptor monoclonal antibody plus palliative chemotherapy as a first-line treatment for recurrent or metastatic nasopharyngeal carcinoma
    Chen, Chen
    Zhou, Yixin
    Zhang, Xuanye
    Fu, Sha
    Lin, Zuan
    Fang, Wenfeng
    Yang, Yunpeng
    Huang, Yan
    Zhao, Hongyun
    Hong, Shaodong
    Zhang, Li
    CANCER MEDICINE, 2020, 9 (05): : 1721 - 1732
  • [30] Risk factor analysis for anti-epidermal growth factor receptor monoclonal antibody-induced skin toxicities in real-world metastatic colorectal cancer treatment
    Saito, Yoshitaka
    Uchiyama, Kazuki
    Takekuma, Yoh
    Komatsu, Yoshito
    Sugawara, Mitsuru
    SUPPORTIVE CARE IN CANCER, 2023, 31 (08)